Literature DB >> 6713906

Repeated confidence intervals for group sequential clinical trials.

C Jennison, B W Turnbull.   

Abstract

We describe methods for the construction of valid confidence intervals for parameters of interest at repeated times during the course of a clinical trial with two treatments. This approach gives the investigator a way to monitor the trial and allows greater flexibility than methods that have rigid statistical stopping rules. Two situations are considered. In the first, responses are available immediately and normally distributed, the parameter of interest being the difference in means. In the second, observations are survival times and a proportional hazards model is assumed. Here the parameter of interest is the hazard ratio. Group sequential tests can be based on repeated confidence interval methods and these are compared to other multiple testing procedures that have been proposed.

Mesh:

Year:  1984        PMID: 6713906     DOI: 10.1016/0197-2456(84)90148-x

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  13 in total

1.  Survivor function estimators under group sequential monitoring based on the logrank statistic.

Authors:  Malka Gorfine
Journal:  Lifetime Data Anal       Date:  2003-06       Impact factor: 1.588

2.  Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment.

Authors:  M Rosenblum; M J Van der Laan
Journal:  Biometrika       Date:  2011-12       Impact factor: 2.445

3.  Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Authors:  Sanjiv S Agarwala; Sandra J Lee; Waiki Yip; Uma N Rao; Ahmad A Tarhini; Gary I Cohen; Douglas S Reintgen; Terry L Evans; Joanna M Brell; Mark R Albertini; Michael B Atkins; Shaker R Dakhil; Robert M Conry; Jeffrey A Sosman; Lawrence E Flaherty; Vernon K Sondak; William E Carson; Michael G Smylie; Alberto S Pappo; Richard F Kefford; John M Kirkwood
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

4.  The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial.

Authors:  Philippe Armand; Haesook T Kim; Marie-Michele Sainvil; Paulina B Lange; Angela A Giardino; Veronika Bachanova; Steven M Devine; Edmund K Waller; Neera Jagirdar; Alex F Herrera; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Steven L McAfee; Robert J Soiffer; Yi-Bin Chen; Joseph H Antin
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

5.  Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring of Clinical Trials.

Authors:  Lingling Li; Scott R Evans; Hajime Uno; L J Wei
Journal:  Stat Biopharm Res       Date:  2009-11-01       Impact factor: 1.452

6.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.

Authors:  Huiyan Luo; Jin Lu; Yuxian Bai; Teng Mao; Jun Wang; Qingxia Fan; Yiping Zhang; Kuaile Zhao; Zhendong Chen; Shegan Gao; Jiancheng Li; Zhichao Fu; Kangsheng Gu; Zhihua Liu; Lin Wu; Xiaodong Zhang; Jifeng Feng; Zuoxing Niu; Yi Ba; Helong Zhang; Ying Liu; Li Zhang; Xuhong Min; Jing Huang; Ying Cheng; Dong Wang; Yu Shen; Qing Yang; Jianjun Zou; Rui-Hua Xu
Journal:  JAMA       Date:  2021-09-14       Impact factor: 56.272

7.  Confidence intervals for the selected population in randomized trials that adapt the population enrolled.

Authors:  Michael Rosenblum
Journal:  Biom J       Date:  2013-04-03       Impact factor: 2.207

8.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Konstantin Penkov; John Haanen; Brian Rini; Laurence Albiges; Matthew T Campbell; Balaji Venugopal; Christian Kollmannsberger; Sylvie Negrier; Motohide Uemura; Jae L Lee; Aleksandr Vasiliev; Wilson H Miller; Howard Gurney; Manuela Schmidinger; James Larkin; Michael B Atkins; Jens Bedke; Boris Alekseev; Jing Wang; Mariangela Mariani; Paul B Robbins; Aleksander Chudnovsky; Camilla Fowst; Subramanian Hariharan; Bo Huang; Alessandra di Pietro; Toni K Choueiri
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

9.  A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer.

Authors:  Konstantin H Dragnev; Jeremy D Whyman; Cynthia K Hahn; Peter E Kebbekus; Sarah F Kokko; Sunil M Bhatt; James R Rigas
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

10.  Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials.

Authors:  Ying Lu; Lu Tian
Journal:  Stat Biopharm Res       Date:  2020-10-09       Impact factor: 1.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.